MedTrace Logo

Anti-inflammatory Effects of Enriched Enteral Nutrition During Human Experimental Endotoxemia

NCT01100996 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2011-06-07

No results posted yet for this study

Summary

During sepsis and septic shock the immune response can be overwhelming leading to excessive tissue damage, organ failure and death. Ideally, the inflammatory response is modulated leading to both adequate protection to invading pathogens as well as limitation of an exuberant immune response. In the last years, experimental evidence has been accumulating that enteral administration of lipid-enriched nutrition attenuates inflammation and preserves organ integrity in several inflammatory models. The current study investigates the immune-modulating potential of enriched enteral nutrition in a human setting of experimental endotoxemia.

Conditions

  • Endotoxemia

Interventions

OTHER

control enteral nutrition

This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates

OTHER

enriched enteral feeding

This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Johannes Van der Hoeven, PhD, MD · Department of Intensive Care Medicine, Radboud University Nijmegen Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01100996 on ClinicalTrials.gov